The DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.
Current treatment paradigms and emerging therapies for NAFLD/NASH
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, may culminate into cirrhosis and hepatocellular cancer (HCC) and is presently a leading cause of liver transplant. Although a steady progress is seen in understanding of the disease epidemiology, pathogenesis and identifying therapeutic targets, the slowest advancement is seen in the therapeutic field. Currently, there is no FDA approved therapy for this disease and appropriate therapeutic targets are urgently warranted. In this review we discuss the role of lifestyle intervention, pharmacological agents, surgical approaches, and gut microbiome, with regard to therapy for NASH. In particular, we focus the role of insulin sensitizers, thyroid hormone mimetics, antioxidants, cholesterol lowering drugs, incretins and cytokines as therapeutic targets for NASH. We highlight these targets aiming to optimize the future for NASH therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–204 of 204
New drugs for non‐alcoholic steatohepatitis
Cardoso, A. C., de Figueiredo-Mendes, C., Villela‐Nogueira, C. A., & Sanyal, A. J. (2020) · Liver International · doi:10.1111/liv.14354 · Cited by 29
Thyroid hormones and thyromimetics: a new approach to nonalcoholic steatohepatitis?
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2020) · Hepatology · doi:10.1002/hep.31204 · Cited by 17
Type 1 diabetes: Through the lens of human genome and metagenome interplay
Vahed, S. Z., Sani, H. M., Saadat, Y. R., Barzegari, A., & Omidi, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.052 · Cited by 17
Li, X., & Li, C. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5987 · Cited by 16
Cited by
Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
Myint, M., Oppedisano, F., De Giorgi, V., Kim, B.-M., Marincola, F. M., Alter, H. J., & Nesci, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04627-0 · Cited by 61
Yadav, P., Khurana, A., Bhatti, J. S., Weiskirchen, R., & Navik, U. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106426 · Cited by 32
Shrestha, S., Jeon, J.-H., & Hong, C.-W. (2025) · BMB Reports · doi:10.5483/bmbrep.2024-0058 · Cited by 30
Perspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25
Vega Joubert, M. B., Degrave, V., Ingaramo, P., Oliva, M. E., & D'Alessandro, M. E. (2022) · Food & Function · doi:10.1039/d2fo02216h · Cited by 20
Metadata
- Authors
- Raza, S.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2021
- Volume
- 26
- Issue
- 2
- Pages
- 206-237
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/4892
- OpenAlex
- W3092194487
- Cited by
- 310
- References
- 204
- FWCI
- 21.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.